[Cyclosporin A eyedrops in the prevention of high-risk corneal graft rejection. II. Postoperative clinical results].
Twenty-four patients (25 eyes) presenting a high corneal rejection risk have been treated by an association of topical cyclosporine A (2% in castor oil) and Dexamethasone eyedrops 1% 48 h preoperatively, the posology was slowly degressive postoperatively. The mean follow-up is of 12 months. Results are 19 clear grafts among which 4 had a reversible reject reaction, 3 unreversible rejections with a totally cloudy graft (12%), 3 corneal graft oedema of nonimmunologic nature allowing a counting fingers vision. A control group of 25 patients with the same high risks of rejection treated only by topical corticosteroids followed up for the same mean time showed an obvious higher rate of failure (65%).
Goichot-Bonnat
L
L
Chemla
P
P
Pouliquen
Y
Y
D000328:Adult; D000368:Aged; D003318:Corneal Opacity / Q000209:etiology / Q000601:surgery; D016039:Corneal Transplantation; D003524:Cyclosporins / Q000008:administration & dosage*; D003907:Dexamethasone / Q000627:therapeutic use; D005260:Female; D005500:Follow-Up Studies; D006084:Graft Rejection / Q000187:drug effects*; D006801:Humans; D008297:Male; D008875:Middle Aged; D009883:Ophthalmic Solutions; D011184:Postoperative Period; D011292:Premedication; D012306:Risk; D013601:T-Lymphocytes / Q000187:drug effects
D003524:Cyclosporins; D009883:Ophthalmic Solutions; D003907:Dexamethasone
Cyclosporine A collyre dans la prévention du rejet de greffe de cornée à haut risque. II. Résultats cliniques post-opératoires.